Fulltext

Live Virus Vaccines in Transplantation: Friend or Foe?

Verolet, Charlotte ; Posfay-Barbe, Klara

In: Current Infectious Disease Reports, 2015, vol. 17, no. 4, p. 1-11

Add to personal list
    Title
    • Live Virus Vaccines in Transplantation: Friend or Foe?
    Author
    • Verolet, Charlotte. Pediatric Infectious Diseases Unit, Division of General Pediatrics, Department of Pediatrics, University Hospitals of Geneva & University of Geneva Medical School, Geneva, Switzerland
    • Posfay-Barbe, Klara. Pediatric Infectious Diseases Unit, Division of General Pediatrics, Department of Pediatrics, University Hospitals of Geneva & University of Geneva Medical School, Geneva, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Current Infectious Disease Reports, 2015, vol. 17, no. 4, p. 1-11. Springer US; http://www.springer-ny.com
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:332009
    Summary
    Solid organ and hematopoietic stem cell transplant recipients may be exposed to diseases which may be prevented through live attenuated virus vaccines (LAVV). Because of their immunosuppression, these diseases can lead to severe complications in transplant recipients. Despite increasing evidence regarding the safety and effectiveness of certain LAVV, these vaccines are still contraindicated for immunocompromised patients, such as transplant recipients. We review the available studies on LAVV, such as varicella zoster, measles-mumps-rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. We discuss the current recommendations and the potential risks, as well as the expected benefits of LAVV immunization in this population.